The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients With Non-V30M Transthyretin Amyloidosis
NCT00630864
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
21
Enrollment
INDUSTRY
Sponsor class
Conditions
Transthyretin-associated Amyloidosis With Polyneuropathy
Interventions
DRUG:
Fx-1006A
Sponsor
Pfizer